<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520101</url>
  </required_header>
  <id_info>
    <org_study_id>LYTEN</org_study_id>
    <nct_id>NCT03520101</nct_id>
  </id_info>
  <brief_title>Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses. The 'LYTEN' Trial</brief_title>
  <official_title>Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses: A Pilot Prospective Randomized Trial. The 'LYTEN' Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment with transcatheter aortic valve implantation (TAVI) of patients with small
      (≤23mm) surgical bioprostheses remains a challenge due to the increased transvalvular
      residual gradients and high rates of severe prosthesis-patient mismatch (PPM) following the
      procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized open-label trial including patients with
      surgical aortic bioprosthetic dysfunction in the presence of a small (≤23mm; inner diameter
      ≤21 mm) stented surgical valve. Following the Heart Team'S decision to proceed with a
      TAVI-ViV procedure, patients will be randomized to either receive an Edwards (SAPIEN XT or
      SAPIEN 3) valve or a CoreValve Evolut R or Evolut PRO system. New iterations of these valve
      models may also be included.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multicenter, randomized trial including patients with surgical aortic bioprosthetic dysfunction in the presence of a small stented surgical valve. Patients will be randomized to either receive an Edwards (SAPIEN XT or SAPIEN 3) valve or a Core Valve Evolut R or Evolut PRO system.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Valve performance</measure>
    <time_frame>30 days</time_frame>
    <description>Severe prothesis-patient mismatch (PPM) (defined as an index aortic valve area ≤0.65 cm2/m2) and/or moderate-severe aortic regurgitation (AR) (VARC-2 definition).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Residual transvalvular gradient</measure>
    <time_frame>30 days</time_frame>
    <description>Residual (maximal and mean) transvalvular gradient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transvalvular gradient.</measure>
    <time_frame>1-year</time_frame>
    <description>Maximal and mean transvalvular gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve performance : Moderate or severe PPM moderate-severe AR at 30 days and 1 year.</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Moderate or severe PPM; moderate-severe AR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined endpoints: Moderate-severe AR or severe PPM at 1-year follow-up.</measure>
    <time_frame>1 year</time_frame>
    <description>Moderate-severe AR or severe PPM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety endpoints</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>individually and combined: death, stroke, major or life threatening bleeding, pacemaker implantation, myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Exercise capacity as evaluated by the six-minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LV hypertrophy</measure>
    <time_frame>30 days and 1 year</time_frame>
    <description>Changes in LV hypertrophy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Regurgitation, Aortic</condition>
  <condition>Prosthesis Failure</condition>
  <arm_group>
    <arm_group_label>SAPIEN</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COREVALVE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI_ViV procedure with Edwards valve</intervention_name>
    <description>The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is &gt;18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.</description>
    <arm_group_label>SAPIEN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI_ViV procedure with CoreValve system</intervention_name>
    <description>The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.</description>
    <arm_group_label>COREVALVE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with surgical aortic bioprosthetic dysfunction defined as severe aortic
             stenosis and/or regurgitation approved for a ViV procedure by the Heart Team

          -  Stented surgical valves.

          -  Small (≤23mm) surgical valve

        Exclusion Criteria:

        - Stentless or sutureless surgical valves
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Rodés-Cabau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Universitaire de Cardiologie et de Pneumologie de Québec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josep Rodés-Cabeau, MD</last_name>
    <phone>418-656-8711</phone>
    <email>josep.rodes@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Pelletier Beaumont, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3929</phone_ext>
    <email>emilie.pelletier-beaumont@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <phone>418-656-8711</phone>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Emilie Pelletier Beaumont, MSc</last_name>
      <phone>418-656-8711</phone>
      <email>emilie.pelletier-beaumont@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Prosthesis Failure</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

